Immune Checkpoint Inhibitor-Associated Transverse Myelitis
Immune checkpoint inhibitors (ICIs) are highly effective in treating cancer and are increasingly used. Thus, awareness of various complications in the form of immunity-related adverse events is increasing. Transverse myelitis following ICIs is a rare but severe neurological adverse event, and inform...
Gespeichert in:
Veröffentlicht in: | Duzce medical journal 2024-10 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | Duzce medical journal |
container_volume | |
creator | Sarıdaş, Furkan Hojjati, Farid Koç, Emine Rabia Turan, Ömer Faruk |
description | Immune checkpoint inhibitors (ICIs) are highly effective in treating cancer and are increasingly used. Thus, awareness of various complications in the form of immunity-related adverse events is increasing. Transverse myelitis following ICIs is a rare but severe neurological adverse event, and information about this entity is minimal. ICI-associated transverse myelitis should be considered a rapid and comprehensive differential diagnosis after evaluating infective, metabolic, or other inflammatory-autoimmune pathologies. After diagnosis, early immunomodulation is required through intravenous high-dose methylprednisolone, IVIg, or plasmapheresis. It should be kept in mind that different etiologies may coexist or a superimposed condition may cause each other, and concurrent treatment should not be delayed. Further studies are needed to investigate the neurological manifestations that may develop in association with these therapies further and help establish guidelines for their management. In this case report, a rare case of ICI-associated transverse myelitis in a 62-year-old male patient was presented. |
doi_str_mv | 10.18678/dtfd.1494742 |
format | Article |
fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_18678_dtfd_1494742</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_18678_dtfd_1494742</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_18678_dtfd_14947423</originalsourceid><addsrcrecordid>eNqVzjsPgjAUBeDGaCJRRvf-AZBCw8PNEI0MbgxuTYVLqPJKbzXh3_sIg6tnOWc4w0fIhnkui8Mo3pamKl3GEx5xf0YsFniRE0bsMv_ZS2Ij3rx3gsTnMbfILmvbRwc0raG4D73qDM26Wl2V6bWzR-wLJQ2UNNeywydoBHoeoVFG4ZosKtkg2FOviHM85OnJKXSPqKESg1at1KNgnvgaxccoJmPw7_8FxvREyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Immune Checkpoint Inhibitor-Associated Transverse Myelitis</title><source>DOAJ Directory of Open Access Journals</source><creator>Sarıdaş, Furkan ; Hojjati, Farid ; Koç, Emine Rabia ; Turan, Ömer Faruk</creator><creatorcontrib>Sarıdaş, Furkan ; Hojjati, Farid ; Koç, Emine Rabia ; Turan, Ömer Faruk</creatorcontrib><description>Immune checkpoint inhibitors (ICIs) are highly effective in treating cancer and are increasingly used. Thus, awareness of various complications in the form of immunity-related adverse events is increasing. Transverse myelitis following ICIs is a rare but severe neurological adverse event, and information about this entity is minimal. ICI-associated transverse myelitis should be considered a rapid and comprehensive differential diagnosis after evaluating infective, metabolic, or other inflammatory-autoimmune pathologies. After diagnosis, early immunomodulation is required through intravenous high-dose methylprednisolone, IVIg, or plasmapheresis. It should be kept in mind that different etiologies may coexist or a superimposed condition may cause each other, and concurrent treatment should not be delayed. Further studies are needed to investigate the neurological manifestations that may develop in association with these therapies further and help establish guidelines for their management. In this case report, a rare case of ICI-associated transverse myelitis in a 62-year-old male patient was presented.</description><identifier>ISSN: 1307-671X</identifier><identifier>EISSN: 1307-671X</identifier><identifier>DOI: 10.18678/dtfd.1494742</identifier><language>eng</language><ispartof>Duzce medical journal, 2024-10</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-crossref_primary_10_18678_dtfd_14947423</cites><orcidid>0009-0003-3716-4463 ; 0000-0001-5945-2317 ; 0000-0002-6752-1519 ; 0000-0002-0264-7284</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Sarıdaş, Furkan</creatorcontrib><creatorcontrib>Hojjati, Farid</creatorcontrib><creatorcontrib>Koç, Emine Rabia</creatorcontrib><creatorcontrib>Turan, Ömer Faruk</creatorcontrib><title>Immune Checkpoint Inhibitor-Associated Transverse Myelitis</title><title>Duzce medical journal</title><description>Immune checkpoint inhibitors (ICIs) are highly effective in treating cancer and are increasingly used. Thus, awareness of various complications in the form of immunity-related adverse events is increasing. Transverse myelitis following ICIs is a rare but severe neurological adverse event, and information about this entity is minimal. ICI-associated transverse myelitis should be considered a rapid and comprehensive differential diagnosis after evaluating infective, metabolic, or other inflammatory-autoimmune pathologies. After diagnosis, early immunomodulation is required through intravenous high-dose methylprednisolone, IVIg, or plasmapheresis. It should be kept in mind that different etiologies may coexist or a superimposed condition may cause each other, and concurrent treatment should not be delayed. Further studies are needed to investigate the neurological manifestations that may develop in association with these therapies further and help establish guidelines for their management. In this case report, a rare case of ICI-associated transverse myelitis in a 62-year-old male patient was presented.</description><issn>1307-671X</issn><issn>1307-671X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqVzjsPgjAUBeDGaCJRRvf-AZBCw8PNEI0MbgxuTYVLqPJKbzXh3_sIg6tnOWc4w0fIhnkui8Mo3pamKl3GEx5xf0YsFniRE0bsMv_ZS2Ij3rx3gsTnMbfILmvbRwc0raG4D73qDM26Wl2V6bWzR-wLJQ2UNNeywydoBHoeoVFG4ZosKtkg2FOviHM85OnJKXSPqKESg1at1KNgnvgaxccoJmPw7_8FxvREyQ</recordid><startdate>20241009</startdate><enddate>20241009</enddate><creator>Sarıdaş, Furkan</creator><creator>Hojjati, Farid</creator><creator>Koç, Emine Rabia</creator><creator>Turan, Ömer Faruk</creator><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0009-0003-3716-4463</orcidid><orcidid>https://orcid.org/0000-0001-5945-2317</orcidid><orcidid>https://orcid.org/0000-0002-6752-1519</orcidid><orcidid>https://orcid.org/0000-0002-0264-7284</orcidid></search><sort><creationdate>20241009</creationdate><title>Immune Checkpoint Inhibitor-Associated Transverse Myelitis</title><author>Sarıdaş, Furkan ; Hojjati, Farid ; Koç, Emine Rabia ; Turan, Ömer Faruk</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_18678_dtfd_14947423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sarıdaş, Furkan</creatorcontrib><creatorcontrib>Hojjati, Farid</creatorcontrib><creatorcontrib>Koç, Emine Rabia</creatorcontrib><creatorcontrib>Turan, Ömer Faruk</creatorcontrib><collection>CrossRef</collection><jtitle>Duzce medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sarıdaş, Furkan</au><au>Hojjati, Farid</au><au>Koç, Emine Rabia</au><au>Turan, Ömer Faruk</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune Checkpoint Inhibitor-Associated Transverse Myelitis</atitle><jtitle>Duzce medical journal</jtitle><date>2024-10-09</date><risdate>2024</risdate><issn>1307-671X</issn><eissn>1307-671X</eissn><abstract>Immune checkpoint inhibitors (ICIs) are highly effective in treating cancer and are increasingly used. Thus, awareness of various complications in the form of immunity-related adverse events is increasing. Transverse myelitis following ICIs is a rare but severe neurological adverse event, and information about this entity is minimal. ICI-associated transverse myelitis should be considered a rapid and comprehensive differential diagnosis after evaluating infective, metabolic, or other inflammatory-autoimmune pathologies. After diagnosis, early immunomodulation is required through intravenous high-dose methylprednisolone, IVIg, or plasmapheresis. It should be kept in mind that different etiologies may coexist or a superimposed condition may cause each other, and concurrent treatment should not be delayed. Further studies are needed to investigate the neurological manifestations that may develop in association with these therapies further and help establish guidelines for their management. In this case report, a rare case of ICI-associated transverse myelitis in a 62-year-old male patient was presented.</abstract><doi>10.18678/dtfd.1494742</doi><orcidid>https://orcid.org/0009-0003-3716-4463</orcidid><orcidid>https://orcid.org/0000-0001-5945-2317</orcidid><orcidid>https://orcid.org/0000-0002-6752-1519</orcidid><orcidid>https://orcid.org/0000-0002-0264-7284</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1307-671X |
ispartof | Duzce medical journal, 2024-10 |
issn | 1307-671X 1307-671X |
language | eng |
recordid | cdi_crossref_primary_10_18678_dtfd_1494742 |
source | DOAJ Directory of Open Access Journals |
title | Immune Checkpoint Inhibitor-Associated Transverse Myelitis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A20%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20Checkpoint%20Inhibitor-Associated%20Transverse%20Myelitis&rft.jtitle=Duzce%20medical%20journal&rft.au=Sar%C4%B1da%C5%9F,%20Furkan&rft.date=2024-10-09&rft.issn=1307-671X&rft.eissn=1307-671X&rft_id=info:doi/10.18678/dtfd.1494742&rft_dat=%3Ccrossref%3E10_18678_dtfd_1494742%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |